Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Cocrystal Pharma to post earnings of ($0.55) per share for the quarter.
Cocrystal Pharma Price Performance
NASDAQ COCP opened at $1.53 on Thursday. The company has a 50 day simple moving average of $1.89 and a 200-day simple moving average of $1.94. The firm has a market capitalization of $15.57 million, a price-to-earnings ratio of -0.83 and a beta of 2.35. Cocrystal Pharma has a 52-week low of $1.35 and a 52-week high of $3.26.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
